Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemoglobin-vesicles as a transfusion alternative.

Eishun Tsuchida1, Hiromi Sakai, Hirohisa Horinouchi

  • 1Advanced Research Institute for Science & Engineering, Waseda University, Tokyo, Japan. eishun@waseda.jp

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
|November 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxygenated Perfusion Enhances Hepatocyte Function in Human iPSC-liver Tissue.

Transplantation·2026
Same author

Protective effects of hemoglobin vesicles on intestinal ischemia-reperfusion injury in a rat model of thoracic aortic occlusion.

JVS-vascular science·2026
Same author

Impact of haemoglobin vesicles on pretransfusion testing and mitigation strategies.

Vox sanguinis·2026
Same author

Haemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative: an open-label, single-centre phase Ib study protocol in Japan.

BMJ open·2026
Same author

Rheological Properties of Hemoglobin-Based Physical and Chemical Gels, and Their Hybrid.

ACS omega·2026
Same author

A Case of Lung Volume Reduction Surgery in a Young Adult With Chronic Lung Disease.

Respirology case reports·2025

Hemoglobin vesicles (HbV) offer a safe, storable blood transfusion alternative. Their unique structure ensures oxygen transport and minimizes side effects, paving the way for clinical trials.

Area of Science:

  • Biomedical Engineering
  • Hematology
  • Nanotechnology

Background:

  • Current blood transfusion methods face limitations including antigen compatibility and pathogen transmission risks.
  • Human hemoglobin (Hb) is a potential oxygen carrier but requires protection from degradation and side effects.
  • Liposome encapsulation of Hb (Hb-vesicle, HbV) presents a cell-like structure for improved safety and stability.

Purpose of the Study:

  • To evaluate the safety, efficacy, and characteristics of hemoglobin vesicles (HbV) as a blood substitute.
  • To assess the impact of HbV's cellular structure on biological interactions and oxygen transport.
  • To outline the development pathway for HbV towards clinical application.

Main Methods:

  • Encapsulation of purified human hemoglobin within phospholipid vesicles (liposomes) to create HbV.

Related Experiment Videos

  • Characterization of HbV particle size (approx. 250 nm) and stability for storage.
  • In vivo studies including microcirculatory observations, hemodilution, hemorrhagic shock resuscitation, biodistribution, and metabolism in animal models.

    • Main Results:

    • HbV demonstrated effective oxygen-carrying capacity in animal models of extreme hemodilution and shock.
    • The cellular structure of HbV mitigated adverse reactions with endothelial cells and vasorelaxation factors.
    • Biodistribution studies showed HbV is cleared by the reticuloendothelial system within a week.
    • HbV are free from blood-type antigens and infectious viruses, offering long-term storage stability.

    Conclusions:

    • Hemoglobin vesicles (HbV) represent a promising cell-free oxygen carrier with a favorable safety profile.
    • The unique structure of HbV is crucial for its efficacy and reduced side effects.
    • Further development, including GMP production and clinical trials, is planned for this innovative blood substitute.